NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

579.60 -22.50 (-3.74%)

25.05% Fall from 52W High

853.6K NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

25,299.5

Market Cap

Below industry Median

0.6

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

14 Nov 2022

579.60

-3.74%

Brand performance remains mixed but execution (focus) is improving

Accumulate: Emami Ltd.

ICICI Securities Limited

Emami reported a slightly patchy revenue performance with (consol.) revenue growth of 3% - both adjusted revenue growth YoY (explained below) and 3-year CAGR were 8%. RM pressure, inferior product mix and higher ad-spends (much appreciated) led to lower margins (EBITDA print of 24%).

Emami Ltd. has an average target of 763.29 from 7 brokers.

Emami Ltd.

11 Nov 2022

579.60

-3.74%

EMAMI LTD

Accumulate: Emami Ltd.

Target

Prabhudas Lilladhar

Emami Ltd.'s price crossed below 30Day SMA today

Emami Ltd.

18 Aug 2022

579.60

-3.74%

EARNINGS UPDATE- EMAMI 1QFY23

Buy: Emami Ltd.

Target

Chola Wealth Direct

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

29 Jul 2022

579.60

-3.74%

EMAMI LTD

Accumulate: Emami Ltd.

Target

Prabhudas Lilladhar

Emami Ltd. has an average target of 763.29 from 7 brokers.

Emami Ltd.

19 May 2022, 12:00AM

579.60

-3.74%

Emami

Buy: Emami Ltd.

Target

Khambatta Securities

Emami Ltd.'s price crossed below 30Day SMA today

Emami Ltd.

29 Mar 2022

579.60

-3.74%

Dermicool acquisition: Fairly valued, but not significant

Buy: Emami Ltd.

Target

Motilal Oswal

HMN recently announced the acquisition of the Dermicool brand from Reckitt Benckiser India for INR4.32b. We estimate ~INR1.4b in FY23 sales for Dermicool, with an EBITDA of INR475m, translating in an acquisition cost of ~3x sales and ~9x EBITDA. COVID-led restrictions affected summer season sales in the last two years, impacting overall category growth. Hence, its CY21 sales of INR1.13b are not representative. We believe CY19 sales of INR1.33b are a better representation. The deal will be funded through internal accruals....

Emami Ltd. is trading below all available SMAs

Emami Ltd.

27 Mar 2022

579.60

-3.74%

EMAMI LTD

Accumulate: Emami Ltd.

Target

Prabhudas Lilladhar

Near term growth remains a concern given slowdown in rural demand and sharp jump in input costs in past month. While we expect 2/3% price increase in April, poor demand and high inflation will impact profit growth in 1H23 on a high base. We cut EPS estimates of FY23/24 by 5.9/1.3% amidst near term uncertainty. We estimate 11.7% PAT CAGR over FY22-24 and value the stock at 30xDec23 EPS and assign a value of Rs607/share. We believe Rs1.6bn...

Emami Ltd.'s price crossed below 50Day SMA today

Emami Ltd.

13 Feb 2022

579.60

-3.74%

Emami

Buy: Emami Ltd.

Khambatta Securities

Emami Ltd. is trading below all available SMAs

Emami Ltd.

03 Feb 2022

579.60

-3.74%

EMAMI LTD

Accumulate: Emami Ltd.

Prabhudas Lilladhar

Navratna therapy, Kesh King onion range, Crme 21 products, however it will have any significant impact in a few years only. Although inflation in LLP and Rice bran oil remains high, 3-4% price increase and cost control will enable Emami prevent any significant margin erosion. We estimate 12% PAT CAGR over FY22-24 and value the stock at 30xDec23 EPS and assign a value of Rs624/share. We believe Rs1.6bn buyback (Max...

Promoters unpledged 2.89% of shares in last quarter. Total pledge stands at 10.50% of promoter holdings

Is Emami Ltd. worth buying?

225 Votes:

Buy 74.67%

Sell 17.33%

Hold 8.0%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf